|Bid||52.73 x 900|
|Ask||52.75 x 1000|
|Day's Range||52.52 - 52.62|
|52 Week Range||44.76 - 55.00|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||9.15|
|Forward Dividend & Yield||1.93 (3.67%)|
|Ex-Dividend Date||May 03, 2021|
|1y Target Est||63.88|
The world has settled for flu vaccines that are no more than 50% effective, so a better product could reshape the market, and perhaps expand it.
Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate. The trial will evaluate several dose levels of both vaccine formulations given to healthy adults 18 - 49 years of age. Interim data from the trial is
Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.